Cardiff Oncology (CRDF) Operating Expenses (2011 - 2026)

Cardiff Oncology has reported Operating Expenses for 15 years, with the latest figure at $8.1 million in Q4 2025.

• Quarterly Operating Expenses fell 36.57% year-over-year to $8.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $49.6 million (changed 0.44% YoY) and the FY2025 annual result came in at $49.6 million, changed 0.44% from the prior year.
• Operating Expenses fell to $8.1 million in Q4 2025 per CRDF's latest filing, from $12.1 million in the prior quarter.
• Over five years, Operating Expenses peaked at $14.9 million in Q2 2025 and troughed at $5.5 million in Q1 2021.
• A 5-year average of $10.7 million and a median of $11.0 million in 2023 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2022 and 2025: Operating Expenses soared 102.18% in 2022, then slumped 36.57% in 2025.
• Over 5 years, Operating Expenses stood at $9.7 million in 2021, then retreated by 1.44% to $9.5 million in 2022, then gained by 10.17% to $10.5 million in 2023, then climbed by 21.31% to $12.7 million in 2024, then plunged by 36.57% to $8.1 million in 2025.
• According to Business Quant data, Operating Expenses over the past three periods registered $8.1 million, $12.1 million, and $14.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.